Andere talen Theravance Biopharma, Inc.

Aandelen

TBPH

KYG8807B1068

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,44 ^USD	-6,12%		-8,46%	-24,91%

12/04	Sectorupdate: Aandelen gezondheidszorg vrijdagmiddag lager	MT
12/04	Aandelen Theravance Biopharma stijgen nadat BTIG de dekking start op Kopen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024	29/04
Sector Update: Health Care Stocks Lower Friday Afternoon	12/04
Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	12/04
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024	10/04
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	01/03
Theravance Bio: Q4 Earnings Snapshot	26/02
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, vs. Street Est of $17.6M	26/02
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	26/02
Theravance Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Theravance Biopharma to Participate in an Upcoming Investor Conference	22/02
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	14/02
Theravance Biopharma Shares Drop Pre-Bell as Phase 4 Study of Lung Disease Treatment Fails to Meet Primary Endpoint	05/01
Top Premarket Decliners	05/01
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)	05/01
Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease	05/01
Theravance Biopharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed.	01/01
Theravance Biopharma : Material Event - Form 8-K	28/12
Theravance Biopharma Announces Appointment of Jeremy Grant to Board of Directors	21/12
Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director	21/12
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors	21/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Theravance Biopharma, Inc.

Aandelen

TBPH

KYG8807B1068

Andere talen

Filters